Focus: IBSA is a mid-sized Swiss pharmaceutical company founded in 1945, specializing in treatments for neurology and gastroenterology with a significant focus on analgesics and nutraceuticals. The company operates at scale with 1,001–5,000 employees and maintains a diversified product portfolio spanning pain management, fertility, and specialty therapeutics.
Profile data last refreshed 9h ago · AI intelligence enriched 1w ago
No open roles listed right now. Follow IBSA Institut Biochimique to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from IBSA Institut Biochimique's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Revenue anchor representing 78% of company revenue; topical NSAID formulation with heparin; sustained exclusivity through 2035 provides multi-year runway.
Help build intelligence for IBSA Institut Biochimique
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Secondary NSAID patch product showing erosion pressure; lacks defined LOE date, indicating near-term generic/biosimilar risk.
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo